Atxn1 — Ataxin 1 is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
Ataxin 1 (ATXN1) is a nuclear protein encoded by the ATXN1 gene on chromosome 6p22.3. It is best known for causing Spinocerebellar Ataxia Type 1 (SCA1), a progressive autosomal dominant neurodegenerative disorder characterized by cerebellar ataxia, motor dysfunction, and cognitive decline. The pathogenic mechanism involves a CAG trinucleotide repeat expansion in the coding region, resulting in an expanded polyglutamine (polyQ) tract in the mutant protein. The gene is catalogued as NCBI Gene ID 6310 and OMIM 601556.
Ataxin 1 is a transcriptional regulator that localizes primarily to the nucleus. Its normal functions include:
-
Transcriptional regulation: Ataxin 1 interacts with various transcription factors and co-repressors
- Binds to RORα (retinoic acid-related orphan receptor alpha)
- Interacts with histone deacetylases (HDACs)
- Modulates Notch signaling
-
RNA processing: Associates with RNA splicing machinery
-
Cellular homeostasis: Involved in protein quality control and cellular stress responses
-
Neuronal function: Critical for Purkinje cell development and maintenance
Ataxin 1 is an 815-amino acid protein with several key domains:
- PolyQ tract: Normal range 6-35 glutamines; expanded to 36-130 in SCA1
- AXH domain: Ataxin-1/hesx1 domain (residues 567-689); mediates protein-protein interactions
- Nuclear localization signal (NLS): Arg/Lys-rich sequence for nuclear import
- Phosphorylation sites: Ser776 phosphorylation is critical for toxicity
- Purkinje cells: Highest expression; primary site of pathology
- Cerebellar cortex: Molecular and granular layers
- Brainstem: Olivary nuclei, pons
- Hippocampus: Lower expression
- Cerebral cortex: Regional expression
Expression data is available from the Allen Human Brain Atlas.
SCA1 is an autosomal dominant neurodegenerative disorder and one of the most common polyglutamine diseases.
- Inheritance: Autosomal dominant
- Mutation: CAG trinucleotide repeat expansion in exon 8
- Normal range: 6-35 repeats
- Full penetrance: >41 repeats
- Intermediate range: 36-39 repeats (reduced penetrance)
Cerebellar symptoms:
- Progressive gait ataxia (first symptom in ~70%)
- Limb ataxia (dysmetria, dysdiadochokinesia)
- Nystagmus (horizontal, vertical, or rotatory)
- Dysarthria (scanning speech)
- Dysphagia (swallowing difficulties)
Extrapyramidal features:
- Parkinsonian features (bradykinesia, rigidity)
- Dystonia
- Chorea (less common)
Brainstem involvement:
- Oculomotor abnormalities
- Vertigo
- Respiratory dysfunction (late)
Cognitive and psychiatric:
- Executive dysfunction
- Memory impairment
- Depression, anxiety
- Psychosis (rare)
Peripheral nervous system:
- Peripheral neuropathy (less prominent than in other SCAs)
- Reduced reflexes
- Age of onset: Typically 30-40 years (can be 4-70 years)
- Disease duration: 10-30 years from onset to death
- Rate of progression correlates with repeat length
- Multiple system atrophy (MSA): Some studies show ATXN1 repeat expansions in rare cases
- SCA1-like phenotypes: ATXN1 variants may modify other ataxias
The expanded polyQ tract in ataxin-1 leads to neurodegeneration through multiple interconnected mechanisms:
¶ 1. Protein Misfolding and Aggregation
- Expanded polyQ promotes abnormal protein folding
- Forms insoluble cytoplasmic and nuclear aggregates
- Sequesters essential cellular proteins
- Impairs ubiquitin-proteasome system
- Alters interactions with transcriptional regulators
- Disrupts RORα-mediated gene expression
- Impairs histone acetylation/deacetylation balance
- Affects neurotrophic factor expression (BDNF)
- Mutant ataxin-1 accumulates in the nucleus
- Alters nuclear pore function
- Impairs nuclear-cytoplasmic transport
- Reduces mitochondrial biogenesis
- Increases oxidative stress
- Impairs calcium homeostasis
- Promotes apoptosis
- The mutant protein loses normal regulatory functions
- Dominant-negative effects on wild-type ataxin-1
- Haploinsufficiency contributions
- Cerebellar degeneration: Loss of Purkinje cells
- Brainstem atrophy: Inferior olivary nuclei, cranial nerve nuclei
- Spinal cord involvement: Spinocerebellar tracts
- Hippocampal pathology: Less severe than cerebellum
- Gold standard: PCR-based CAG repeat sizing
- Confirmatory: Southern blot for large repeats
- Preimplantation testing: Available for family planning
- MRI: Cerebellar and brainstem atrophy
- MR spectroscopy: Reduced N-acetylaspartate in cerebellum
- Diffusion tensor imaging: White matter abnormalities
- Neurological examination: Standardized Ataxia Rating Scales (SARA, ICARS)
- Neuropsychological testing: Cognitive assessment
- Electrophysiology: EMG, nerve conduction studies
¶ Treatment and Management
No cure exists for SCA1. Management is symptomatic and supportive:
- Physical therapy: Gait training, balance exercises
- Occupational therapy: Adaptive devices, home modifications
- Speech therapy: For dysarthria and dysphagia
- Medications:
- Amitriptyline or gabapentin for neuropathic pain
- Clonazepam for myoclonus
- Botulinum toxin for dystonia
| Approach |
Status |
Mechanism |
| ASOs |
Preclinical |
Target ATXN1 mRNA for degradation |
| RNAi |
Preclinical |
siRNA-mediated knock-down |
| CRISPR |
Preclinical |
allele-specific editing |
- HDAC inhibitors: Vorinostat, sodium butyrate (reduce toxic aggregation)
- Autophagy inducers: Rapamycin, trehalose (enhance protein clearance)
- Neurotrophic factors: BDNF mimetics
- Antioxidants: CoQ10, vitamin E
- Riluzole: Modulates glutamate, some benefit in ataxias
- Varenicline: Cholinergic agonist, showed promise in SCA3
- Aminopyridines: For downbeat nystagmus
| Repeat Length |
Age of Onset |
Progression |
Phenotype |
| 36-39 |
~40-50 years |
Slow |
Mild |
| 40-50 |
~30-40 years |
Moderate |
Classic SCA1 |
| 51-70 |
~20-30 years |
Rapid |
Early-onset severe |
| >70 |
<20 years |
Very rapid |
Juvenile onset |
- Identification and characterization of the gene causing type 1 spinocerebellar ataxia. Nat Genet, 1993. PMID: 8275086
- Ataxin-1 nuclear localization and aggregation: role in polyglutamine-induced disease. Cell, 1998. PMID: 9729215
- Mutant ataxin-1 with expanded polyglutamine causes Purkinje cell degeneration and neurobehavioral abnormalities. PNAS, 2004. PMID: 15574502
- SCA1: disease mechanisms and therapeutic targets. Trends in Genetics, 2020.
- Transcriptional dysregulation and cerebellar degeneration in SCA1. Brain, 2021.
- Therapeutic targeting of SCA1. Nature Reviews Neurology, 2021.
- Polyglutamine diseases: emerging therapeutic strategies. Nature Reviews Neurology, 2022.
- Ataxin-1 interacts with RORα in cerebellar Purkinje cells. Neuroscience, 2019.
- [Spinocerebellar Ataxia Type 1[/diseases/[spinocerebellar-ataxias[/diseases/[spinocerebellar-ataxias[/diseases/[spinocerebellar-ataxias--TEMP--/diseases)--FIX--
- [Spinocerebellar Ataxias[/diseases/[spinocerebellar-ataxias[/diseases/[spinocerebellar-ataxias[/diseases/[spinocerebellar-ataxias--TEMP--/diseases)--FIX--
- [Polyglutamine Diseases[/mechanisms/[polyglutamine-diseases[/mechanisms/[polyglutamine-diseases[/mechanisms/[polyglutamine-diseases--TEMP--/mechanisms)--FIX--
- [Cerebellum[/entities/[neurons[/entities/[neurons[/entities/[neurons--TEMP--/entities)--FIX--
- [Genes Index[/[genes[/[genes[/[genes[/genes
- [Proteins Index[/[proteins[/[proteins[/[proteins[/proteins
The study of Atxn1 — Ataxin 1 has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.